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Abstract
Background: Maternal administration of the acyclovir prodrug valacyclovir is compatible with pregnancy and breastfeeding.
However, the safety profile of prolonged infant and maternal exposure to acyclovir in the context of antiretrovirals (ARVs)
for prevention of mother-to-child HIV-1 transmission (PMTCT) has not been described.
Methods: Pregnant Kenyan women co-infected with HIV-1/HSV-2 with CD4 counts . 250 cells/mm
3 were enrolled at 34
weeks gestation and randomized to twice daily 500 mg valacyclovir or placebo until 12 months postpartum. Women
received zidovudine from 28 weeks gestation and single dose nevirapine was given to women and infants at the time of
delivery for PMTCT. Infant blood was collected at 6 weeks for creatinine and ALT. Breast milk specimens were collected at 2
weeks postpartum from 71 women in the valacyclovir arm; acyclovir levels were determined for a random sample of 44
(62%) specimens. Fisher’s Exact and Wilcoxon rank-sum tests were used for analysis.
Results: One hundred forty-eight women were randomized and 146 mother-infant pairs were followed postpartum. PMTCT
ARVs were administered to 98% of infants and all mothers. Valacyclovir was not associated with infant or maternal toxicities
or adverse events, and no congenital malformations were observed. Infant creatinine levels were all normal (, 0.83 mg/dl)
and median creatinine (median 0.50 mg/dl) and infant growth did not differ between study arms. Acyclovir was detected in
35 (80%) of 44 breast milk samples collected at 2 weeks postpartum. Median and maximum acyclovir levels were 2.62 and
10.15 mg/ml, respectively (interquartile range 0.6–4.19).
Conclusions: Exposure to PMTCT ARVs and acyclovir after maternal administration of valacyclovir during pregnancy and
postpartum to women co-infected with HIV-1/HSV-2 was not associated with an increase in infant or maternal toxicities or
adverse events.
Trial Registration: ClinicalTrials.gov NCT00530777
Citation: Drake AL, Roxby AC, Kiarie J, Richardson BA, Wald A, et al. (2012) Infant Safety during and after Maternal Valacyclovir Therapy in Conjunction with
Antiretroviral HIV-1 Prophylaxis in a Randomized Clinical Trial. PLoS ONE 7(4): e34635. doi:10.1371/journal.pone.0034635
Editor: Ravi Jhaveri, Duke University School of Medicine, United States of America
Received October 11, 2011; Accepted March 2, 2012; Published April 11, 2012
Copyright:  2012 Drake et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health (NIH) [R03 HD057773, R03 HD057773–02S1, and K24 AI087399 to CF; K24 HD054314 to
G.J.S.; K24 AI071113 and PO1 AI30731 to AW; University of Washington CFAR (UW CFAR) P30 AI027757; International AIDS Research and Training Program by the
Fogarty International Center (FIC) D43-TW00007; FIC R24 TW007988 to ACR; University of Washington Center for AIDS Research (UW CFAR) core P30 AI027757; UW
CFAR T32 AI0714032 to ALD], University of Washington Department of Epidemiology Small Grants Program; Puget Sound Partners for Global Health Research
Technology Grant to BAR, and University of Washington Royalty Research Fund Grant [4027] to C.F. GlaxoSmithKline donated study drug (http://www.gsk.com).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: ALD, ACR, JK, GJS, BAR, and CF declared that no competing interests exist. AW received grant support from GlaxoSmithKline and has
been a consultant for AiCuris. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: adrake2@uw.edu
Introduction
Herpes simplex virus type 2 (HSV-2) is the most common cause
of genital ulcer disease worldwide. Antiviral treatment for HSV-2
with acyclovir or valacyclovir during pregnancy has been shown to
have important clinical benefits, such as reducing genital shedding
of HSV-2 and genital ulcers during pregnancy, which are risk
factors for mother-to-child HSV-2 transmission. [1] The preva-
lence of HSV-2 infection among HIV-1 infected women is high,
with .75% of women co-infected in some regions. [2,3] Genital
ulcers resulting from HSV-2 infection are more common among
HIV-1 infected women, [4] and have been associated with a 3–5
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34635times higher risk of mother-to-child HIV-1 transmission. [2,5]
Maternal benefits of HSV-2 suppression include reduced frequen-
cy and severity of HSV-2 reactivations, which may also improve
maternal health or reduce risk of HIV-1 transmission.
Valacyclovir is a prodrug of acyclovir, which is rapidly absorbed
and converted to acyclovir and is 3–5 times more bioavailable
than acyclovir. [6,7] Both acyclovir and valacyclovir have good
safety profiles in pregnant women and infants and have not been
associated with congenital malformations or infant toxicity.
[8,9,10] However, the safety profile of these drugs has not been
previously described in the context of zidovudine (ZDV) and
nevirapine (NVP) antiretroviral (ARV) prophylaxis for prevention
of mother-to-child HIV-1 transmission (PMTCT) and data on
prolonged infant exposure to acyclovir through breast milk is
lacking. Acyclovir concentrations are reported to be higher in both
amniotic fluid and breast milk than maternal blood, [11,12] and
data from animal models suggest the combination of acyclovir and
ZDV increases fetal exposure to both drugs. [13] Although
previous data suggests the concentration of acyclovir in breast milk
is low, equivalent to , 2% of a pediatric dose, [12] PMTCT
ARVs may alter the pharmacokinetics of acyclovir in breast milk
compartments.
We evaluated infant safety during and after prolonged maternal
valacyclovir therapy administered in conjunction with antiretro-
virals for PMTCT prophylaxis within a randomized clinical trial of
HSV-2 suppression of twice daily 500 mg valacyclovir versus
placebo in HIV-1/HSV-2 co-infected pregnant and postpartum
Kenyan women. We measured the concentration of acyclovir in
breast milk in order to determine the levels of acyclovir infants
were exposed to through breast milk when dually exposed to
acyclovir and ARV prophylaxis for PMTCT. As a secondary
outcome, we also evaluated the safety of valacyclovir in HIV-1
infected pregnant and postpartum women receiving PMTCT
prophylaxis.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting documentation; see Protocol S1 and
Checklist S1.
Ethics Statement
Written informed consent was obtained from study participants
and all study procedures were approved by ethical review
committees at the University of Washington and the University
of Nairobi.
Study Population
At an antenatal clinic in Nairobi, Kenya, we enrolled 148 HIV-
1/HSV-2 co-infected pregnant women at 34 weeks gestation who
were not eligible for highly active ARV therapy: CD4 . 250 cells/
mm
3 and World Health Organization (WHO) stage 1 or 2
between April 2008 and June 2009. [14] The study was completed
in August 2010 after the last follow-up visit was completed. At
enrollment, women were randomized in a 1:1 allocation scheme to
receive twice daily 500 mg valacyclovir or matching placebo for
the remainder of their pregnancy and for 12 months postpartum.
Women were scheduled for follow-up study visits at 38 weeks
gestation and at 2, 6, 10, and 14 weeks and 6, 9, and 12 months
postpartum. At each study visit a questionnaire was administered
and physical exam conducted, either by a study nurse or by one of
two study physicians. Maternal blood samples were collected at
enrollment and antenatal follow-up for creatinine assays. A breast
milk sample was collected from all women at 2 weeks postpartum
and a convenience sample of 44 breast milk specimens collected
from women in the valacyclovir arm were tested for acyclovir
concentrations (Advion BioSciences, Inc, Ithaca, NY). Advion
BioSciences developed a method for use during this study for
determining acyclovir concentrations in breast milk using liquid
chromatography-mass spectrometry, with a lower limit of
quantification of 0.1 ng/mL. Intra- and inter-assay accuracy
ranges were 212.12% to 12.87% (mean 0.001%) and 11.51% to
24.83% (mean 27.08%), respectively. The ranges (mean) of intra-
and inter-assay precision, measured as percent coefficient of
variability, were 0.44% to 14.5% (4.84%) and 3.01% to 5.83%
(3.71%), respectively. The sample size calculations for the clinical
trial have been previously described [14].
Infants were brought to the clinic at all study visits for physical
exams and blood was collected at 6 weeks for ALT and creatinine
assays. Women were asked to return to the study clinic for interim
visits if they were ill or their infant was ill, and were asked to return
at monthly interim visits for pill refills after the 6 month study visit.
The clinical trial was regularly reviewed by an external data safety
and monitoring board and is registered at http://clinicaltrials.gov
(Identification number NCT00530777).
There were no criteria for stopping the trial, other than safety.
Sequentially numbered study identifiers were randomly generated
by an independent, off-site researcher with block sizes of 20. Study
participants were sequentially enrolled. All study investigators and
participants were blinded until the end of the study.
Adverse Events and Statistical Analysis
Infants that were stillborn or second-born twins were excluded
in the infant analysis. Similarly, women without at least one
antenatal study visit or at least one postpartum study visit were
excluded in the maternal antenatal and postpartum analyses,
respectively. Cause of death and reason for hospitalizations were
collected from study participants and medical records, if available.
In the event of maternal death, cause of death was obtained from
family or community members in addition to available medical
records. The 2004 Division of AIDS Table was used to grade the
severity of adverse events. [15] The incidence of adverse events,
allowing for recurrences, was compared between study arms using
the Andersen-Gill method. [16] The 2006 WHO reference
population was used to calculate age and gender adjusted Z-
scores for infant height and weight. [17] Linear mixed effects
models were constructed to evaluate the effect of maternal
treatment arm on Z-scores for infant height and weight over 12
months of follow-up. Frequencies of categorical variables were
compared using Fisher’s Exact tests and distributions of contin-
uous variables were compared using Wilcoxon rank-sum tests.
Mean baseline HIV-1 RNA levels were compared between arms
using t-tests. Incidence rate ratios (IRR) were calculated to
compare incidence of adverse events between study arms. A Cox
regression model was constructed to evaluate the effect of maternal
study arm on time to infant death. Statistical analyses were
conducted using Stata version 11.1 (StataCorp LP, College
Station, Texas).
Results
A total of 148 women were enrolled in the study, 74
randomized to valacyclovir and 74 randomized to placebo; 146
(99%) completed at least one study visit after delivery and are
included in this analysis. The median age of participants was 25
(interquartile range [IQR], 22–29), 79% were married, and the
median CD4 count was 459 cells/mm
3 (IQR, 342–573 cells/
mm
3). All women received antenatal ZDV for PMTCT; the
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duration of antenatal ZDV use was 9.7 weeks. In addition, 140
(98%) women received PMTCT prophylaxis during labor or
postpartum: 92% single dose nevirapine (sdNVP) in labor, 4 (3%)
postpartum ZDV, 9 (6%) 3TC during labor or postpartum. There
were no differences in baseline demographic or clinical charac-
teristics between women randomized to the valacyclovir or
placebo arms (Table 1). The CONSORT flow diagram has been
previously published [14].
Among the 146 deliveries, 143 infants were live-born infants
and 3 were stillborn (1 valacyclovir, 2 placebo). A total of 85 (59%)
infants were female and median gestational age at delivery was
39.3 weeks. Risk of cesarean section was higher in the valacyclovir
arm (12%) than the placebo arm (7%), but this difference was not
statistically significant (p=0.40). Nearly all (98%) infants received
PMTCT prophylaxis: 137 (96%) sdNVP at birth, 143 (98%)
postnatal ZDV, and 20 (14%) postnatal 3TC. Total infant follow-
up time was similar between arms: 64.6 person-years in placebo
and 68.2 person-years in valacyclovir. The majority of infants
(97%) were breastfed with a median duration of 6.0 months in the
placebo arm and 5.3 months in the valacyclovir arm (IQR 3.4–6.5
months, both arms). Comparison of plasma, cervical and breast
milk HIV-1 viral levels, the primary outcomes of the randomized
clinical trial have been previously described [14].
Infant Safety after Exposure to Acyclovir in Utero and
through Breast Milk
The median duration of in utero exposure to acyclovir was 5.3
weeks (IQR 3.7 – 6.0 weeks). After in utero exposure to maternal
ARV prophylaxis, and acyclovir for women in the valacyclovir
arm, none of the infants were born with congenital malforma-
tions. Median birth weights were similar in infants born to
women in the valacyclovir (3.2 kg, IQR 2.9–3.5) and placebo
(3.0 kg, IQR 2.9–3.5) arms (p=0.09); the proportion of infants
born premature (,37 weeks gestation) was also similar (19% vs.
13%, p=0.36).
During the first year of life, 7 infants in the placebo arm and 2
infants in the valacyclovir arm died (Hazard Ratio (HR) 0.27, 95%
CI: 0.06–1.32, p=0.11) (Table 2). Infant hospitalizations and
deaths by maternal study arm are summarized in Table 2. The
incidence of infant adverse events by study arm is shown in
Table 3. The incidence of pneumonia was somewhat higher
among infants in the valacyclovir arm than the placebo arm (0.39
vs. 0.22 per 100 person-years, p=0.08). Infants in the valacyclovir
arm were less likely to have eczema (IRR 0.29; p=0.02) and oral
thrush (IRR 0.67; p=0.05) than infants in the placebo arm. There
were no other major differences in the incidence of infant adverse
events between study arms. Furthermore, infant growth over time
was similar between arms; there were no significant differences in
the mean change, or rate of change, in Z-scores for infant weight
or height during 12 months of follow-up.
Among the 122 infants with serum collected at 6 weeks, all
creatinine levels were normal and the distribution was similar in
the valacyclovir and placebo arms (median [range]: 0.49 mg/dl
[0.19–0.83] and 0.51 mg/dl [0.30–0.86], respectively). Median
ALT levels at 6 weeks were also similar (26.7 U/L [range 12.6–
52.4] in placebo, 26.5 U/L [range 10.6–70.1] in valacyclovir) and
all levels were within the normal range, with the exception of 1
infant with an ALT level of 70.1 U/L (Grade 1) in the valacyclovir
arm [15].
Among women randomized to valacyclovir, 71 had breast milk
samples collected at 2 weeks postpartum and 44 of these samples
were randomly chosen to test for acyclovir concentrations.
Acyclovir was detected in 35 (80%) breast milk samples; the
median concentration was 2.62 mg/ml (IQR 0.6–4.19) and range
was 0.15 to 10.15 mg/ml. At the 2 week postpartum visit, all
women self-reported the number of doses missed in the last 2 days.
Women with detectable levels of acyclovir were significantly more
likely to report fewer doses missed (p=0.03, Fisher’s Exact).
Among the 9 women with undetectable levels of acyclovir in breast
milk samples, 1 (11%) missed all 4 doses, 2 (22%) missed 2 doses,
and 6 (67%) did not miss any doses. In contrast, among the 35
women with detectable levels of acyclovir none missed all doses, 1
(3%) missed 2 doses, 4 (11%) missed 3 doses, and 30 (80%) did not
miss any doses.
Table 1. Demographic and clinical characteristics of study participants at baseline, by study arm.
Baseline characteristics Median (IQR
1) or n (%) P
Valacyclovir (n=73) Placebo (n=73)
Age (years) 25 (22–30) 25 (22–29) 0.82
Married 57 (78) 58 (79) 1.00
Education (years) 8 (7–12) 8 (7–10) 0.26
Employed 22 (30) 18 (25) 0.58
Monthly rent ($/month)
2,3 24 (19–33) 21 (13–33) 0.29
History of sexually transmitted diseases 20 (27) 18 (25) 0.85
History of genital ulcer disease 10 (14) 13 (18) 0.65
Syphilis seropositive
4 0 (0) 0 (0) -
CD4 count (cells/mm
3) 452 (351–560) 481 (340–598) 0.78
WHO stage
5 0.18
1 68 (93) 62 (85)
2 5 (7) 11 (15)
On ZDV
6 by enrollment 73 (100) 68 (93) 0.06
Plasma HIV-1 RNA (log10 copies/mL)
7 3.89 (3.66–4.11) 3.87 (3.67–4.06) 0.91
doi:10.1371/journal.pone.0034635.t001
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Maternal safety outcomes were analyzed separately for
antenatal and postpartum follow-up. After excluding 43 women
who delivered prior to 38 weeks gestation and 3 women without
an antenatal follow-up sample, 100 women were included in the
pregnancy analysis. Genital ulcers were only found in one woman
in the placebo arm during pelvic exam; none were found in the
valacyclovir arm. Other adverse events for women during
pregnancy were minor and primarily consisted of headache,
cough, vomiting, vaginal discharge, urinary tract infection, and
weight loss. The only adverse event that was more frequent in
women in the valacyclovir group was fever; 5 women reported
fevers in the valacyclovir arm for an incidence of 1.02 per
100 person-years and no fevers were reported in the placebo arm
(p=0.03) (Table 4). Median serum creatinine at enrollment was
the same in both arms (0.74 mg/dL) and all antenatal follow-up
levels fell within the normal range; median creatinine change from
enrollment to 38 weeks gestation was 0.03 mg/dL in the placebo
arm and 0.05 mg/dL in the valacyclovir arm. There were no
hospitalizations or maternal deaths during pregnancy; the only
severe adverse events that occurred during pregnancy were
3 women with stillbirths (above).
There were 73 women in each study arm included in the
postpartum analysis; 1 woman in each arm was lost to follow-up
prior to delivery. The median duration of postpartum follow-up
was 12 months in both arms and the total follow-up time was 69.3
person-years in the valacyclovir arm and 69.8 person-years in the
placebo arm. Overall retention was high with 136 (93%) of women
completing the 12 month postpartum visit; median adherence to
study drug by pill count was 86% in both arms (IQR 80% to 92%).
Three women were hospitalized during postpartum follow-up for
the following reasons: severe depression (valacyclovir); gastroen-
teritis (valacyclovir); and malaria and severe anemia (placebo).
Three women also died during postpartum follow-up. One woman
in the valacyclovir arm died with peripheral edema and chest pain,
which was not considered to be related to the study drug. Two
women died in the placebo arm; one died of a hemorrhage at
3 weeks postpartum and may have had undiagnosed tuberculosis,
and the other died with abdominal pain with vomiting and
diarrhea. The most frequently reported maternal postpartum
adverse events included cough, upper respiratory infections,
headache, backache, chest pain, and abdominal pain; there were
no differences in the incidence of these events between study arms
(Table 5). The risk of dizziness (IRR=0.50, p=0.03) and yeast
infections (IRR 0.36, p=0.04) were higher in the placebo than
valacyclovir arm; incidence of all other reported adverse events
was similar between study arms.
Discussion
We did not detect any association between valacyclovir and
congenital malformations, infant adverse events, or infant
toxicities after exposure in utero and through breast milk following
administration of maternal valacyclovir and PMTCT ARVs
during pregnancy and postpartum. The absence of infant kidney
and liver toxicity suggests that valacyclovir exposure does not
increase the risk of nevirapine-associated liver toxicity. We also
observed that acyclovir was detected in breast milk at low levels at
2 weeks postpartum, demonstrating a low level of infant exposure
to acyclovir through breast milk. The median concentration of
2.62 mg/mL was similar to the average breast milk concentration
reported in a pharmacokinetic study by Sheffield et al conducted in
U.S. women who were not HIV-1 infected. [12] Assuming infants
ingest 750 mL/day of breast milk, the cumulative exposure to
acyclovir for infants in this study over the course of 1 year would
be 717 mg (2.62 mg/mL 6 750 mL/day 6 365 days). For
comparison, this is 79% lower than the cumulative exposure from
Table 2. Infant hospitalizations and deaths, by study arm.
Age Hospitalizations Deaths
Symptoms and diagnoses Cause of death
Placebo (n=8) Valacyclovir (n=8) Placebo (n=7) Placebo (n=2)
Birth – 2 days Neonatal asphyxia as a result of
obstructed labor
Neonatal distress as a result of
nuchal cord
Prematurity
Neonatal asphyxia as a result of
placenta previa
Hyper-extended leg
Mild respiratory distress syndrome Neonatal sepsis
. 2 days – 6 weeks Neonatal sepsis Respiratory distress, possible
neonatal sepsis
Possible neonatal sepsis
. 6 weeks – 6 months Superficial burns Vomiting and diarrhea Malaria, dehydration as a result
of gastroenteritis
Complications of tooth
extraction, diarrhea
Pneumonia Gastroenteritis, dehydration, anemia
(2nd hospitalization)
Gastroenteritis and dehydration
Gastroenteritis, rickets, malaria,
urinary tract infection
Diarrhea Fever, respiratory distress,
abdominal distention
Dehydration, malnutrition Pneumonia, gastroenteritis (3rd
hospitalization)
Gastroenteritis, HIV infection
6–12 months Gastroenteritis, growth retardation,
oral thrush
Meningitis
Gastroenteritis, fever
Pneumonia, rickets
doi:10.1371/journal.pone.0034635.t002
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Symptoms and diagnoses Valacyclovir Placebo Incidence rate ratio P
Incidence per 100 person-years (n)
General
Fever 2.71 (178) 2.90 (181) 0.93 .0.10
Respiratory
Cough 2.62 (173) 2.87 (178) 0.92 .0.10
Upper respiratory infection 3.10 (204) 3.16 (197) 0.98 .0.10
Bronchitis 0.37 (25) 0.30 (19) 1.25 .0.10
Asthma 0.03 (2) 0.05 (3) 0.63 .0.10
Pneumonia 0.39 (26) 0.22 (14) 1.76 0.08
Tuberculosis 0.01 (1) 0.05 (3) 0.32 .0.10
Wheezing 0.21 (14) 0.14 (9) 1.48 .0.10
Difficulty breathing 0.09 (6) 0.22 (14) 0.40 0.06
Rhinorrhea 1.86 (123) 1.85 (116) 1.00 .0.10
Gastrointestinal
Vomiting 0.66 (44) 0.87 (55) 0.76 .0.10
Diarrhea 1.60 (106) 1.48 (93) 1.08 .0.10
Behavioral
Irritability 0.31 (21) 0.42 (27) 0.74 .0.10
Difficulty feeding 0.51 (34) 0.64 (41) 0.79 .0.10
Growth
Wasting 0.63 (6) 0.14 (9) 0.63 .0.10
Cardiovascular
Heart murmur 0.13 (9) 0.08 (5) 1.71 .0.10
Hematological
Anemia
a 0.04 (3) 0.03 (2) 1.42 .0.10
Malaria 0.08 (5) 0.08 (5) 0.94 .0.10
Sepsis 0.13 (9) 0.17 (11) 0.77 .0.10
Allergic
Pruritic dermatitis 0.04 (3) 0.08 (5) 0.57 .0.10
Rash 1.62 (107) 1.71 (107) 0.95 .0.10
Skin
Heat rash 0.49 (33) 0.60 (38) 0.82 .0.10
Eczema 0.06 (4) 0.20 (13) 0.29 0.02
Central nervous system
Seizures 0.01 (1) 0.01 (1) 0.95 .0.10
Encephalopathy 0.03 (2) 0 - .0.10
Lymphatic
Lymphadenopathy 0.06 (4) 0.11 (7) 0.54 .0.10
Head
Fontanelle sunken 0.10 (7) 0.17 (11) 0.60 .0.10
Conjunctivitis 0.34 (23) 0.42 (27) 0.81 .0.10
Oral thrush 0.67 (42) 0.93 (59) 0.67 0.05
Mouth ulcers 0.07 (5) 0.08 (5) 0.95 .0.10
Otitis media 0.09 (6) 0.08 (5) 1.14 .0.10
Otitis externa 0.09 (6) 0.06 (4) 1.42 .0.10
Liver
Jaundice 0.01 (1) 0 - .0.10
aDefined as hemoglobin ,11 g/dl.
doi:10.1371/journal.pone.0034635.t003
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14–21 days [18].
The incidences of adverse events for pregnant and postpartum
women were also similar between study arms, with the exception
of fever during pregnancy which was more frequent among
women in the valacyclovir arm. However, 3 of 5 fevers were
reported only at interim visits and were not measured. Fever has
not previously been reported as a side effect of valacyclovir, and is
unlikely to be related to valacyclovir suppressive therapy.
Our infant and maternal safety results are consistent with prior
studies of HSV-2 antiviral use during pregnancy and breastfeed-
ing. [8,9,19,20] However, safety data on prolonged exposure to
acyclovir in utero and in breast milk from these studies are limited.
Concerns about in utero acyclovir exposure stem from pharmaco-
kinetic data that have shown an accumulation of acyclovir in
amniotic fluid at levels higher than maternal plasma; however,
acyclovir has not been found to accumulate in the fetus. [19,20]
The absence of any clinically significant adverse events in dually
exposed infants suggests the safety profile is similar to infants
exposed to acyclovir or ZDV alone; however, we did not evaluate
pharmacokinetics of acyclovir in infants and could not ascertain
whether PMTCT ARV prophylaxis with ZDV potentiates infant
exposure to acyclovir, as has been suggested in one animal study
[13].
Table 4. Incidence of maternal antenatal adverse events, by study arm.
Symptoms and diagnoses Valacyclovir Placebo Incidence rate ratio P
Incidence per 100 person-years (n)
General
Fever 1.02 (5) 0 - 0.03
Abdominal pain 1.44 (7) 0.83 (4) 1.73 .0.10
Back pain 0.62 (3) 0.84 (4) 0.74 .0.10
Edema 1.04 (5) 0.64 (3) 1.61 .0.10
Weight loss 2.99 (14) 3.39 (15) 0.88 .0.10
Fatigue 0.20 (1) 0 - .0.10
Headache 3.34 (15) 2.10 (10) 1.59 .0.10
Respiratory
Cough 1.69 (8) 2.74 (12) 0.62 .0.10
Cold 0.41 (2) 0.21 (1) 1.97 .0.10
Sneezing 0.41 (2) 0.42 (2) 0.98 .0.10
Nasal congestion 0.41 (2) 0 - .0.10
Rhinorrhea 0 0.63 (3) - .0.10
Gastrointestinal
Nausea 0.41 (2) 0.63 (3) 0.65 .0.10
Vomiting 2.60 (12) 2.02 (9) 1.29 .0.10
Diarrhea 0.41 (2) 0.20 (1) 1.99 .0.10
Heartburn 0.41 (2) 0.21 (1) 1.97 .0.10
Cardiovascular
Hypertension 0.20 (1) 0 - .0.10
Tachycardia 0.20 (1) 0 - .0.10
Hematological
Anemia 0.20 (1) 0.21 (1) 0.97 .0.10
Allergic
Pruritic rash 0 0.21 (1) - .0.10
Dizziness 1.01 (5) 0.83 (4) 1.21 .0.10
Obstetrical/Gynecological
Cervical blood 1.08 (5) 0.21 (1) 5.14 .0.10
Vaginal discharge 4.74 (20) 4.10 (17) 1.16 0.01
Vaginal itching 0.61 (3) 1.27 (6) 0.48 .0.10
Genital ulcer disease 0 0.21 (1) - .0.10
Kidney
Urinary tract infection 10.22 (40) 7.90 (32) 1.29 .0.10
Proteinuria 0.62 (3) 0.63 (3) 0.99 .0.10
Dysuria 1.94 (9) 0.65 (3) 3.00 0.09
doi:10.1371/journal.pone.0034635.t004
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Symptoms and diagnoses Valacyclovir Placebo Incidence rate ratio P
Incidence per 100 person-years (n)
General
Fever 0.42 (29) 0.55 (38) 0.77 .0.10
Abdominal pain 0.66 (45) 0.64 (44) 1.03 .0.10
Sore mouth 0.06 (10) 0.09 (6) 1.68 .0.10
Back pain 0.39 (27) 0.61 (42) 0.64 0.07
Muscle aches 0.03 (2) 0.03 (2) 1.01 .0.10
Joint pain 0.17 (12) 0.29 (20) 0.60 .0.10
Edema 0 0.01 (1) - .0.10
Poor appetite 0.22 (15) 0.23 (16) 0.94 .0.10
Wasting 0.04 (3) 0.04 (3) 1.01 .0.10
Respiratory
Cough 1.11 (46) 1.26 (50) 0.88 .0.10
Upper respiratory tract infection 1.11 (75) 1.20 (82) 0.92 .0.10
Bronchitis 0.06 (4) 0.06 (4) 1.00 .0.10
Pneumonia 0.04 (3) 0.10 (7) 0.43 .0.10
Sore throat 0.42 (29) 0.49 (34) 0.86 .0.10
Pharyngitis 0.17 (12) 0.08 (6) 2.02 .0.10
Tuberculosis 0.03 (2) 0.01 (1) 2.00 .0.10
Wheezing 0 0.04 (3) - .0.10
Rhinorrhea 0.44 (30) 0.33 (23) 1.32 .0.10
Gastrointestinal
Vomiting 0.13 (9) 0.19 (13) 0.70 .0.10
Diarrhea 0.35 (24) 0.32 (22) 1.10 .0.10
Breast
Breast pain 0.13 (9) 0.16 (11) 0.82 .0.10
Nipple bleeding/cracking 0.11 (8) 0.22 (15) 0.54 .0.10
Breast engorgement 0.10 (7) 0.09 (6) 1.18 .0.10
Mastitis 0.03 (2) 0.10 (7) 0.29 .0.10
Breast abscess 0.01 (1) 0.03 (2) 0.50 .0.10
Cardiovascular
Hypertension 0.03 (2) 0 - .0.10
Heart murmur 0.01 (1) 0.03 (2) 0.50 .0.10
Chest pain 0.45 (31) 0.65 (45) 0.69 .0.10
Hematological
Anemia 0.06 (4) 0.06 (4) 1.01 .0.10
Malaria 0.17 (11) 0.28 (17) 0.60 .0.10
Allergic
Pruritic dermatitis 0.32 (22) 0.41 (28) 0.79 .0.10
Dizziness 0.22 (15) 0.43 (30) 0.50 0.03
Skin
Eczema 0.04 (3) 0.07 (5) 0.60 .0.10
Opportunistic Infection
Shingles 0.01 (1) 0.04 (3) 0.34 .0.10
Oral thrush 0.03 (2) 0.10 (7) 0.29 .0.10
Mouth ulcers 0.04 (3) 0.01 (1) 3.02 .0.10
Gynecological
Vaginal discharge 0.04 (3) 0.19 (13) 1.16 0.01
Yeast infection 0.07 (5) 0.2 (15) 0.34 0.03
Genital ulcer disease 0.01 (1) 0.03 (2) 0.50 .0.10
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assays and clinical indicators to ascertain infant and maternal
safety both during pregnancy and for 1 year postpartum, captured
serial infant growth measurements, and evaluated safety exposure
to valacyclovir in combination with PMTCT ARVs. However, our
study was subject to some limitations. We were unable to
determine infant acyclovir concentrations, lacked knowledge
regarding the timing between dosing and breast milk sample
collection, and did not evaluate infant neutropenia, which has
been observed in some neonates with herpes treated with high
dose intravenous acyclovir. [21] In addition, we cannot determine
whether acyclovir was not detected in breast milk for some women
in the valacyclovir arm due to over-reporting adherence, the
inability of our assay to detect low concentrations of acyclovir, or
because breast milk sample collection occurred too long after the
last dose was administered. Although we did not detect any
difference in congenital malformations between study arms,
valacyclovir suppressive therapy was started late in pregnancy, at
34 weeks gestation, and we are unable to address risk at earlier
gestations. Finally, use of block randomization could compromise
allocation concealment and lead to selection bias; however we did
not detect any statistical differences in maternal baseline
characteristics between arms.
Acyclovir and valacyclovir are currently used in developed
settings for chronic HSV-2 suppression, including pregnant
women with recurrent genital herpes. [22] Our study provides
additional safety information on tolerability and safety of acyclovir
during late pregnancy, and it includes longer follow-up of than
prior studies of valacyclovir in the US (12 months vs. 2 weeks). [23]
Antiviral use in resource-limited settings may become more
widespread, due to the frequency and severity of HSV-2
reactivations in HIV-1 infected persons coupled with WHO
recommendations to use acyclovir for syndromic management of
lesions consistent with genital herpes. In addition, HSV-2
suppressive therapy slows HIV-1 disease progression. [24] If
antivirals for HSV do become more widely used in HIV-1/HSV-2
co-infected individuals, demonstrating infant and maternal safety
of dual exposure to valacyclovir and PMTCT ARVs could help to
expand the benefit of HSV-2 suppression in resource-limited
settings to pregnant or breastfeeding women.
Maternally administered valacyclovir suppressive therapy used
in conjunction with short-course PMTCT ARVs was well
tolerated among infants and HIV-1 infected pregnant and
postpartum women. Our data suggest PMTCT ARVs do not
alter the safety profile of valacyclovir in these women and their
perinatally exposed infants; valacyclovir suppression should be
considered as a mechanism to reduce HSV-2 recurrences during
late pregnancy and breastfeeding among HIV-1 infected women
receiving short course ARVs for PMTCT, when clinically
indicated.
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